Fig. 1.

MSLN expression is increased in NSCLC patients with BM. A Schematic illustration of the selection process of brain metastasis(BM) derivatives in mice. Parent cells PC9 and H2030 were inoculated into the left ventricle of nude mice to isolate and collect tumor cells with BM. The selection process was carried out twice, and the high-brain metastatic subpopulation (PC9-BrM and H2030-BrM cell lines) were collected. B Differential protein volcano map between PC9-BrM cells and PC9 cells. C Western blot analysis showed that PC9-BrM and H2030-BrM cells with high metastatic activity had higher MSLN protein levels. D Representative images and quantification analysis of MSLN staining in primary lung tumor (LT, n=36) and NSCLC-derived brain metastases (BM, n=34) surgical specimens. (scale bar, 200 μm) . E ELISA detection of MSLN expression in serum of all patients and control groups. HC, healthy controls (n=24). ELC, early-stage NSCLC (n=22). BoM, lung cancer with bone metastasis (n=23). LM, lung cancer with live metastasis (n=20). LCBM, lung cancer with brain metastasis (n=42). PBT, primary brain tumor (n=23). F Kaplan-Meier analysis of the overall survival of 478 lung cancer patients in the GEPIA database. (Data are presented as mean ± SD)